公司資料
ALX Oncology 股價、新聞與催化劑
- 股票代碼:
- ALXO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.97 USD (+0.51%)
收盤價
最後更新: 2026年8月17日
240M USD
市值
股價為何變動
As of Aug 17, 2026, ALXO closed up 0.51% at $1.97. No new same-company headline was identified in the current news window.
公司概覽
CD47-Directed Immuno-Oncology
ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells.
Evorpacept
Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other anticancer medicines. Current development emphasizes HER2-positive cancers and biomarker-selected patients with high CD47 expression.
ALX2004
ALX2004 is a next-generation clinical candidate that expands the company's innate-immunity pipeline beyond evorpacept and is undergoing initial safety evaluation.
未來催化劑
- Initial safety data from the Phase 1 study of ALX2004 in the second half of 2026.
- Topline data from the Phase 2 ASPEN-09-Breast study of evorpacept in mid-2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。